Managing Conflicts of Interest - Why an Independent IRB Should be Part of an Institution’s Policy

Dr. Stuart Horowitz, PhD, MBA | Institutional Services

Research involving institutional and IRB member conflict of interest (COI) happens often, and can lead to concerns about the introduction of bias into research conduct. Read why institutions should consider independent IRBs as part of their institutional COI policy, and why sponsors and CROs should ensure that their sites have conflict of interest policies in place.

Download this whitepaper to learn more.

About the Author

Stuart Horowitz has over 30 years of experience as a research professional. He began his career as a laboratory research investigator and advanced to leadership positions in both translational and clinical research in academic health centers. He has been instrumental in building and improving research programs at medical schools and hospitals throughout the US and the Middle East, as a consultant and Managing Director at Huron Consulting Group. He is currently on the editorial and advisory boards of Clinical Researcher and Therapeutic Innovation and Research Science (TIRS).
Follow on Linkedin More Content by Dr. Stuart Horowitz, PhD, MBA | Institutional Services

Previous Flipbook

Addressing the Challenges of Human Tissues and Cell Products Regulation

Next Flipbook

Towards Total Quality Management in Human Research Protection Programs: IRB Administrative and Reviewer Activities

New Blog: "Ask the IRB Experts"

Visit Blog

Return to Home

Managing Conflicts of Interest - Why an Independent IRB Should be Part of an Institution’s Policy

About the Author

Previous Flipbook

Next Flipbook

Other content in this Stream

In 2018 WIRB approved 100% of the single-patient EA requests that were submitted for review.

The IRB at Inova Health System of Falls Church, VA, began working with a central IRB 15 years ago. Since then, the IRB developed a well-organized process for its partnerships with independent IRBs.

On January 21, 2019, most federally funded research will need to follow the 2018 Requirements of the Common Rule. This post talks through the original and revised rules, and how they may apply to you.

Daniel Kavanagh, PhD, responds to recent news of germline editing of human embryos in China.

The impact of participant payments on clinical trial recruitment.

Studies show clinical trial participants want to know what was learned from their involvement. Many sponsors are implementing plans to deliver plain language summaries to trial participants.

Often, the only way for potential research subjects to learn about a clinical trial is through recruitment materials. But what materials must you submit to the IRB for review?